drugset / Trial / NCT03463473
A Phase I Study of MSB2311 in Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase I study to determine the safety and toxicity, PK/PD, immunogenicity, biomarkers, anti-tumor activity and establish a preliminary recommended Phase 2 dose (RP2D) in subjects with advanced solid tumors.
Timeline
- Start
- 2018-04-12
- Primary completion
- 2020-06-01
- Completion
- 2020-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MSB2311 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | MSB2311 | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | MSB2311 | Monoclonal antibody | 20 mg/kg | Intravenous |